To the Editor: We thank Drs. Tasca, Hilsenroth, and Thompson-Brenner for their comments on our study. The letter gives us the opportunity, as the clinicians and researchers responsible for developing the psychoanalytic treatment and designing the randomized controlled trial, to emphasize that the psychoanalytic therapy employed in our trial is one particular version of psychodynamic psychotherapy. As we pointed out in the article, other psychodynamic approaches to the treatment of bulimia nervosa exist, and among these are treatments integrating more structured behavioral interventions directed specifically toward the core symptoms of bulimia nervosa (1). Thus, while our study does not support the efficacy of the specific version of psychoanalytic psychotherapy for bulimia nervosa used in the trial, in our opinion the obvious implication of the study is that a psychodynamic therapy with a more directive approach to the bulimic symptoms should be tested in future clinical trials. This would be in accordance with the continuous development and enhancement of cognitive-behavioral therapy (CBT) for bulimia through the previous decades.